Progenity Inc. (NASDAQ: PROG) stock plunged by 5.7% at last close on Friday. Progenity, Inc. is a biotechnology firm that develops products for women’s health, gastrointestinal health, and oral biotherapeutics.
PROG stock’ Important Upcoming Event
Progenity has informed that it will attend the 11th annual Partnership Opportunities in Drug Delivery (PODD) Conference, which will take place in Boston on October 28-29, 2021. Chris Wahl, MD, MBA, Progenity’s Vice President of Strategy and Operations, will speak on the panel “Orally Ingestible Devices for Biologics Delivery” on Friday, October 29 at 9:35 a.m. ET. The conference will be live-streamed and accessible to registered participants for three months after the event on request.
Progenity’s Oral Biotherapeutic Administration System (OBDS), which is designed to provide needle-free systemic delivery of large-molecule biologics in a liquid formulation, will be discussed during the session. The business will interact with new and current pharmaceutical partners in addition to participating in the discussion. Progenity has struck its third agreement with a major pharmaceutical firm to use the OBDS platform to study the delivery of big molecules.
Insight of Oral Biotherapeutic Delivery System (OBDS),
The Oral Biotherapeutic Delivery System (OBDS) from Progenity is an orally administered capsule. It allows big molecules like monoclonal antibodies, peptides, and nucleic acids to be delivered orally without the need of needles. These chemicals are currently given via injection because they cannot withstand stomach acids and are too big to be absorbed in the gut. The OBDS capsule is designed to pass through the digestive tract and activate in the small intestine, where it will employ liquid jet release to inject the medication straight into the small intestine for maximum bioavailability.
What more does OBDS offers?
The OBDS platform is meant to deliver liquid drugs without the requirement for reformulation, allowing for industry-leading dosage of more than 50 mg of proteins and more than 5 mg of peptides. As a result, the technique is suitable to a wide range of big molecule candidates. When compared to existing injectable regimens, oral delivery holds great possibility to improve medication effectiveness and safety by allowing for more frequent dosing.